ENO2 and lung carcinoma: However, our study showed that the patients with elevated baseline NSE levels faced a 1.7‐fold increased risk of worse OS compared to those with normal NSE levels, suggesting that NSE may hold prognostic value in lung cancer patients receiving anlotinib therapy.